Medical-testing companies disagree on potential impact of gene patent ruling

Much has changed since 1990, when geneticist Mary Claire King first located the breast-cancer gene at the heart of the case the Supreme Court is hearing this spring. As genetic testing has entered everyday medicine, many companies offer a range of tests, and some sequence a patient’s entire genome seeking clues to disease. Figuring out who owns the rights to all those genes isn’t easy.

That is why some of the medical-testing industry’s bigger players are finding gene patents can be as much a hindrance as a help, even if they own a few themselves. Should the high court decide that individual genes are products of nature and can’t be patented, they see equal or faster growth in the already fast-growing business.

View the original article here: Gene Patents Face Reckoning

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend